At the very outset, the text clarifies the term “neuromuscular disorders” as including the diseases of the motor unit having four components, namely motor neurons in the brainstem or ventral horn of the spinal cord, peripheral nerve, neuromuscular junction and muscle fibers innervated by a single motor neuron. In spite of the fact that the motor unit is under upper motor neuron control, such suprasegmental disorders as cerebral palsy are not included under neuromuscular disorders. An important point to bear in mind is that clinical evaluation of neuromuscular system should never miss out on muscle bulk, tone and strength. Moreover, in laboratory evaluation, important investigations include serum enzymes like creatine phosphokinase, nerve conduction velocity, electromyography, muscle biopsy (most vital), nerve biopsy (usually from sural nerve), ECG and serial pulmonary function tests. From this point, the text moves on to neuromuscular transmission disorders (myasthenia gravis), motor neuron disorders (spinal muscular atrophy), and muscular dystrophies, endocrinal and metabolic myopathies. Pseudohypertrophy muscular dystrophy/Duchenne muscular dystrophy is dealt with at length supported by clinical illustrations showing stages of Gower sign. The future role of molecular genetic engineering as a cure for DMD through myoblast transfer therapy, introduction of a recombinant dystrophin gene ligated to an appropriate promoter by intramuscular injection, or use of retroviruses with viral DNA incorporating the deleted nucleotide sequences of dystrophin gene is highlighted.